

Supplementary Figure 6. Pembrolizumab increases Kv1.3 activity long term in resting responder PBTs. (A) KCa3.1 (left) and Kv1.3 (right) activity reported as conductance (G) from TN (n = 163 cells from 33 patients) and PT (n = 106 and 105 cells, respectively, from 21 patients) resting PBTs. **(B)** KCa3.1 (left) and Kv1.3 (right) activity (G) from individual post-resection (PR) resting PBTs from control (PR-CTR) (n = 35 cells, respectively, from 7 patients) and pembrolizumab (PR-αPD1) (n = 75 cells from 15 patients) patients. **(C)** KCa3.1 (left) and Kv1.3 (right) activity (G) from PT resting PBTs from non-responder (NR) (n = 56 and 55, respectively cells from 11 patients) and responder (R) (n = 50 cells from 10 patients) patients and from KCa3.1 (left) and Kv1.3 (right) activity (G) from individual PR resting PBTs (r-PBTs) from NR (n = 40 cells from 8 patients) and R (n = 35 cells from 7 patients) patients. **(A-C)** Data are represented as box plots: line indicates the median; lower box is the 25th percentile; upper box is the 75th percentile; and whiskers represent the 10th and 90th percentiles. Data compared using Mann-Whitney Rank Sum test. On average we recorded 4-5 cells/patient.